Summary

The global Pharmaceutical CDMO Services market size is predicted to grow from US$ 143442 million in 2025 to US$ 240452 million in 2032; it is expected to grow at a CAGR of 7.5% from 2026 to 2032.

Pharmaceutical CDMO Services refer to outsourced contract development and manufacturing services provided to pharmaceutical and biotechnology companies across the drug development lifecycle, covering activities from process and formulation development through clinical supply, scale-up, commercial manufacturing and selected lifecycle-management services. The market spans small-molecule drug substances and finished dosage forms, biologics, and increasingly advanced modalities such as antibody-drug conjugates, peptides, oligonucleotides, mRNA, viral vectors and cell and gene therapies. Core service capabilities include route and process development, analytical development, cell-line and upstream/downstream process development where applicable, technology transfer, API or drug-substance manufacturing, oral solid dose production, sterile fill-finish, lyophilization, packaging and regulatory-supporting CMC activities. The research scope primarily covers third-party development and GMP manufacturing activities undertaken under contract for pharmaceutical, biotechnology and emerging drug developers, with market demand ultimately driven by the size and complexity of externalized pharmaceutical R&D and manufacturing pipelines.

Key Findings
Pharmaceutical CDMO demand is shifting from standalone manufacturing toward integrated development-to-commercialization partnerships

Small molecules remain the broadest service base while biologics and advanced modalities generate the strongest capacity investment

Sterile injectable and fill-finish capacity has become strategically important amid growing demand for complex injectable therapies

North America remains the largest demand center while Asia continues strengthening its role in pharmaceutical development and manufacturing outsourcing

Leading CDMOs increasingly compete through technology platforms, regulatory execution, global capacity networks and supply-chain resilience

Market Trends
The Pharmaceutical CDMO Services market is moving toward a more integrated, technology-intensive and strategically embedded outsourcing model. Pharmaceutical companies increasingly prefer partners capable of supporting programs from early CMC development through clinical manufacturing, regulatory submission, scale-up and commercial supply, reducing technology-transfer interfaces and execution risk. Thermo Fisher Scientific’s Patheon platform now positions its offering across small molecules, large molecules, advanced therapies, clinical trials and commercial services, while Lonza is similarly integrating drug-substance, drug-product and advanced-modality capabilities across the development lifecycle. At the same time, outsourcing demand is becoming more technically complex. Antibody-drug conjugates, bispecific antibodies, peptides, oligonucleotides, mRNA/LNP products, high-potency APIs, viral vectors and cell therapies require specialized containment, analytical methods, purification technologies and increasingly flexible manufacturing platforms. Single-use bioprocessing, intensified upstream processes, digital quality systems, automated fill-finish and platform-based development are therefore becoming important competitive differentiators. FUJIFILM Biotechnologies’ 2026 expansion in the UK and its investment in specialized biologics processing illustrate continued capital deployment toward flexible biologics capacity, while Lonza continues to accelerate integrated biologics development timelines and advanced-modality manufacturing.

Market Dynamics
Drivers

The principal growth driver is the continued increase in pharmaceutical R&D complexity combined with drug developers’ need to control fixed manufacturing investment. Emerging biotechnology companies frequently lack commercial-scale plants, comprehensive analytical laboratories and global regulatory manufacturing infrastructure, while larger pharmaceutical companies increasingly externalize selected development and manufacturing steps to improve asset utilization and pipeline flexibility. Growth in biologics, injectable medicines, antibody-drug conjugates, peptides, oligonucleotides and other technically demanding modalities further increases the economic value of specialized outsourcing. Another important driver is speed to clinic and speed to market: established platform processes, qualified GMP infrastructure and existing regulatory inspection histories can shorten technology-transfer and facility-readiness timelines compared with building internal capabilities. Lonza, for example, is marketing integrated biologics programs with IND readiness in as little as six months for selected programs, demonstrating how development speed itself has become a core CDMO value proposition.

Restraints
The market remains constrained by high capital intensity, long facility qualification cycles and utilization risk. Biologics plants, sterile fill-finish facilities, high-potency API suites and advanced-therapy sites require substantial investment before customer demand is fully secured, creating the possibility of excess capacity when biotechnology financing or clinical pipelines weaken. Customer qualification and technology transfer can also take months or years, making new capacity difficult to monetize immediately. For drug developers, outsourcing does not eliminate operational risk: dependence on a limited number of qualified manufacturing sites can create scheduling constraints, while transferring complex processes between CDMOs can require comparability work, validation and regulatory submissions. These factors increase switching costs and can slow customer migration even when alternative capacity becomes available.

Opportunities
The most attractive opportunities are shifting toward integrated and technically differentiated platforms rather than commoditized manufacturing alone. ADC conjugation and fill-finish, high-potency APIs, peptides and oligonucleotides, mRNA and lipid nanoparticles, complex biologics, viral vectors and cell therapies offer opportunities for providers able to combine process development, analytical capabilities and GMP manufacturing. Sterile drug-product capacity also remains strategically valuable as injectable biologics and metabolic-disease therapies expand. Geographic supply-chain diversification presents another opportunity: pharmaceutical customers increasingly value dual sourcing and manufacturing networks capable of supporting North America, Europe and Asia under consistent quality systems. Samsung Biologics, for example, reports 845 kL of current total biomanufacturing capacity across its Korean and U.S. facilities and is developing additional capacity, illustrating how scale and multi-site flexibility are becoming strategic competitive tools.

Challenges
The major risks are execution quality, regulatory compliance, customer concentration and demand mismatch. A failed batch, warning letter, contamination event or delayed inspection can affect multiple customer programs and materially damage a CDMO’s reputation. Advanced modalities create additional challenges because manufacturing platforms and regulatory expectations continue to evolve, making standardized production more difficult than for mature oral solid-dose products. Competition for experienced process engineers, analytical scientists and quality personnel also limits rapid capacity expansion. Meanwhile, customers increasingly demand shorter development timelines, flexible batch sizes, stronger supply guarantees and competitive pricing simultaneously, requiring CDMOs to invest ahead of revenue while maintaining compliance and utilization. Consolidation can also reshape available third-party capacity: following Novo Holdings’ acquisition of Catalent, three former Catalent fill-finish facilities were transferred to Novo Nordisk, demonstrating how ownership changes can directly alter the independent manufacturing capacity available to the outsourcing market.

Industry Chain Analysis
The Pharmaceutical CDMO Services industry chain begins with upstream suppliers of pharmaceutical raw materials, intermediates, excipients, cell-culture media, resins, single-use assemblies, filters, vials, syringes, stoppers, analytical reagents and specialized production equipment. Midstream CDMOs convert these inputs and customer intellectual property into validated processes, clinical or commercial drug substance and finished drug products through process development, analytical development, technology transfer, GMP manufacturing, fill-finish, testing and packaging. Value creation is concentrated not simply in physical production capacity but in regulatory track record, process know-how, analytical capability, yield improvement, batch reliability, technology platforms and the ability to transfer a molecule from development to commercial scale without disrupting product quality. Downstream customers include large pharmaceutical groups, established biotechnology companies, emerging biotech companies and virtual pharmaceutical developers. As drug modalities become more complex, the value chain is becoming increasingly interconnected: cell-line development, drug-substance manufacturing, formulation, fill-finish and analytical release testing are more frequently sourced from one integrated partner to reduce coordination risk.

Segment Insights
From a service-stage perspective, commercial manufacturing represents the most stable recurring component of the market because approved drugs can generate multi-year production contracts and substantial switching costs. Development and clinical manufacturing are more fragmented but strategically important because successful early-stage projects can convert into larger commercial contracts. This creates a strong incentive for integrated CDMOs to engage customers before pivotal clinical development rather than competing only for mature commercial products. Drug-substance and drug-product integration is becoming particularly important for biologics and sterile products, where process knowledge, formulation compatibility and fill-finish scheduling directly affect supply reliability.

By modality, conventional small molecules remain the broadest segment in terms of molecule count and manufacturing technologies, covering APIs, highly potent compounds, oral solids and sterile products. Biologics represent a more capital-intensive and rapidly evolving part of the outsourcing market, while ADCs, peptides, oligonucleotides, mRNA and cell and gene therapies form smaller but higher-complexity specialist segments. Leading providers are increasingly building modality-specific platforms rather than treating these products as extensions of conventional manufacturing. AGC Biologics, for example, supports mammalian and microbial biologics, cell therapy, viral vectors, plasmid DNA and mRNA, reflecting the widening technical scope of modern biopharmaceutical CDMOs.

Downstream Market Opportunities
Large pharmaceutical companies remain critical customers for commercial-scale supply, network optimization and specialized technologies, but emerging and virtual biotechnology companies provide an important source of development-stage demand because many operate without internal GMP manufacturing infrastructure. The highest-value opportunities increasingly arise where a CDMO can remain with an asset throughout its lifecycle—from process development and IND-enabling manufacturing to pivotal trials, validation and commercial production. This model increases customer retention while reducing repeated technology-transfer costs. Demand is also broadening from traditional outsourcing of mature products toward strategic capacity reservation, second-source manufacturing and integrated CMC partnerships, particularly for biologics, sterile injectables and advanced modalities where qualified capacity cannot be added rapidly.

Regional Insights
North America remains the largest demand center for Pharmaceutical CDMO Services because of its concentration of innovative pharmaceutical and biotechnology companies, deep clinical pipelines and substantial demand for biologics, sterile injectables and advanced therapies. The United States is simultaneously becoming a stronger manufacturing investment destination as customers emphasize domestic and regional supply security. FUJIFILM Biotechnologies’ Holly Springs facility was selected for the U.S. FDA PreCheck pilot in 2026, reflecting the policy and industry focus on expanding domestic pharmaceutical manufacturing capabilities. Europe retains a strong position in complex chemistry, APIs, biologics, sterile injectables, peptides and specialty manufacturing, supported by established clusters in Switzerland, Germany, France, Italy, the UK and Scandinavia. Asia is increasingly important both as a demand market and manufacturing base. China has developed significant capabilities across small-molecule discovery-to-manufacturing services, biologics, ADCs and advanced modalities through companies such as WuXi AppTec, WuXi Biologics, Asymchem, Pharmaron and Porton, while South Korea has become a major large-scale biologics manufacturing hub led by Samsung Biologics. Japan-linked groups including FUJIFILM, AGC and Ajinomoto Bio-Pharma Services provide additional global capacity and specialized technology platforms.

Report Scope
LPI (LP Information)' newest research report, the “Pharmaceutical CDMO Services Industry Forecast” looks at past sales and reviews total world Pharmaceutical CDMO Services sales in 2025, providing a comprehensive analysis by region and market sector of projected Pharmaceutical CDMO Services sales for 2026 through 2032. With Pharmaceutical CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical CDMO Services industry.

This Insight Report provides a comprehensive analysis of the global Pharmaceutical CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Pharmaceutical CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pharmaceutical CDMO Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical CDMO Services.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical CDMO Services market by product type, application, key players and key regions and countries.

Market Segmentation
Segmentation by Type:
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO

Segmentation by Development Stage:
Clinical Stage
Commercial Stage
Other

Segmentation by Product Form:
Small Molecule CDMO
Biologics CDMO
Cell and Gene Therapy CDMO
Peptide and Oligonucleotide CDMO

Segmentation by Application:
Pharmaceutical Company
Biotechnology Company
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Societal CDMO
Fermion
Ascendia Pharmaceuticals
Ardena
UPM Pharmaceuticals
Groupe Parima
TBD Pharmatech
MedPharm
Lundbeck

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pharmaceutical CDMO Services Market Size (2021-2032)
2.1.2 Pharmaceutical CDMO Services Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Pharmaceutical CDMO Services by Country/Region (2021, 2025 & 2032)
2.2 Pharmaceutical CDMO Services Segment by Type
2.2.1 API CDMO
2.2.2 FDF CDMO
2.2.3 Packaging CDMO
2.2.4 Clinical CDMO
2.2.5 Pharmaceutical CDMO Services Market Size by Type
2.2.5.1 Pharmaceutical CDMO Services Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Pharmaceutical CDMO Services Market Size Market Share by Type (2021-2026)
2.3 Pharmaceutical CDMO Services Segment by Development Stage
2.3.1 Clinical Stage
2.3.2 Commercial Stage
2.3.3 Other
2.3.4 Pharmaceutical CDMO Services Market Size by Development Stage
2.3.4.1 Pharmaceutical CDMO Services Market Size CAGR by Development Stage (2021 VS 2025 VS 2032)
2.3.4.2 Global Pharmaceutical CDMO Services Market Size Market Share by Development Stage (2021-2026)
2.4 Pharmaceutical CDMO Services Segment by Product Form
2.4.1 Small Molecule CDMO
2.4.2 Biologics CDMO
2.4.3 Cell and Gene Therapy CDMO
2.4.4 Peptide and Oligonucleotide CDMO
2.4.5 Pharmaceutical CDMO Services Market Size by Product Form
2.4.5.1 Pharmaceutical CDMO Services Market Size CAGR by Product Form (2021 VS 2025 VS 2032)
2.4.5.2 Global Pharmaceutical CDMO Services Market Size Market Share by Product Form (2021-2026)
2.5 Pharmaceutical CDMO Services Segment by Application
2.5.1 Pharmaceutical Company
2.5.2 Biotechnology Company
2.5.3 Other
2.5.4 Pharmaceutical CDMO Services Market Size by Application
2.5.4.1 Pharmaceutical CDMO Services Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Pharmaceutical CDMO Services Market Size Market Share by Application (2021-2026)

3 Pharmaceutical CDMO Services Market Size by Player
3.1 Pharmaceutical CDMO Services Market Size Market Share by Player
3.1.1 Global Pharmaceutical CDMO Services Revenue by Player (2021-2026)
3.1.2 Global Pharmaceutical CDMO Services Revenue Market Share by Player (2021-2026)
3.2 Global Pharmaceutical CDMO Services Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Pharmaceutical CDMO Services by Region
4.1 Pharmaceutical CDMO Services Market Size by Region (2021-2026)
4.2 Global Pharmaceutical CDMO Services Annual Revenue by Country/Region (2021-2026)
4.3 Americas Pharmaceutical CDMO Services Market Size Growth (2021-2026)
4.4 APAC Pharmaceutical CDMO Services Market Size Growth (2021-2026)
4.5 Europe Pharmaceutical CDMO Services Market Size Growth (2021-2026)
4.6 Middle East & Africa Pharmaceutical CDMO Services Market Size Growth (2021-2026)

5 Americas
5.1 Americas Pharmaceutical CDMO Services Market Size by Country (2021-2026)
5.2 Americas Pharmaceutical CDMO Services Market Size by Type (2021-2026)
5.3 Americas Pharmaceutical CDMO Services Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Pharmaceutical CDMO Services Market Size by Region (2021-2026)
6.2 APAC Pharmaceutical CDMO Services Market Size by Type (2021-2026)
6.3 APAC Pharmaceutical CDMO Services Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Pharmaceutical CDMO Services Market Size by Country (2021-2026)
7.2 Europe Pharmaceutical CDMO Services Market Size by Type (2021-2026)
7.3 Europe Pharmaceutical CDMO Services Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Pharmaceutical CDMO Services by Region (2021-2026)
8.2 Middle East & Africa Pharmaceutical CDMO Services Market Size by Type (2021-2026)
8.3 Middle East & Africa Pharmaceutical CDMO Services Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 Global Pharmaceutical CDMO Services Market Forecast
10.1 Global Pharmaceutical CDMO Services Forecast by Region (2027-2032)
10.1.1 Global Pharmaceutical CDMO Services Forecast by Region (2027-2032)
10.1.2 Americas Pharmaceutical CDMO Services Forecast
10.1.3 APAC Pharmaceutical CDMO Services Forecast
10.1.4 Europe Pharmaceutical CDMO Services Forecast
10.1.5 Middle East & Africa Pharmaceutical CDMO Services Forecast
10.2 Americas Pharmaceutical CDMO Services Forecast by Country (2027-2032)
10.2.1 United States Market Pharmaceutical CDMO Services Forecast
10.2.2 Canada Market Pharmaceutical CDMO Services Forecast
10.2.3 Mexico Market Pharmaceutical CDMO Services Forecast
10.2.4 Brazil Market Pharmaceutical CDMO Services Forecast
10.3 APAC Pharmaceutical CDMO Services Forecast by Region (2027-2032)
10.3.1 China Pharmaceutical CDMO Services Market Forecast
10.3.2 Japan Market Pharmaceutical CDMO Services Forecast
10.3.3 Korea Market Pharmaceutical CDMO Services Forecast
10.3.4 Southeast Asia Market Pharmaceutical CDMO Services Forecast
10.3.5 India Market Pharmaceutical CDMO Services Forecast
10.3.6 Australia Market Pharmaceutical CDMO Services Forecast
10.4 Europe Pharmaceutical CDMO Services Forecast by Country (2027-2032)
10.4.1 Germany Market Pharmaceutical CDMO Services Forecast
10.4.2 France Market Pharmaceutical CDMO Services Forecast
10.4.3 UK Market Pharmaceutical CDMO Services Forecast
10.4.4 Italy Market Pharmaceutical CDMO Services Forecast
10.4.5 Russia Market Pharmaceutical CDMO Services Forecast
10.5 Middle East & Africa Pharmaceutical CDMO Services Forecast by Region (2027-2032)
10.5.1 Egypt Market Pharmaceutical CDMO Services Forecast
10.5.2 South Africa Market Pharmaceutical CDMO Services Forecast
10.5.3 Israel Market Pharmaceutical CDMO Services Forecast
10.5.4 Turkey Market Pharmaceutical CDMO Services Forecast
10.6 Global Pharmaceutical CDMO Services Forecast by Type (2027-2032)
10.7 Global Pharmaceutical CDMO Services Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Pharmaceutical CDMO Services Forecast

11 Key Players Analysis
11.1 Lonza
11.1.1 Lonza Company Information
11.1.2 Lonza Pharmaceutical CDMO Services Product Offered
11.1.3 Lonza Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Lonza Main Business Overview
11.1.5 Lonza Latest Developments
11.2 Catalent
11.2.1 Catalent Company Information
11.2.2 Catalent Pharmaceutical CDMO Services Product Offered
11.2.3 Catalent Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Catalent Main Business Overview
11.2.5 Catalent Latest Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Information
11.3.2 Thermo Fisher Scientific Pharmaceutical CDMO Services Product Offered
11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Thermo Fisher Scientific Main Business Overview
11.3.5 Thermo Fisher Scientific Latest Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Information
11.4.2 Samsung Biologics Pharmaceutical CDMO Services Product Offered
11.4.3 Samsung Biologics Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Samsung Biologics Main Business Overview
11.4.5 Samsung Biologics Latest Developments
11.5 Fareva
11.5.1 Fareva Company Information
11.5.2 Fareva Pharmaceutical CDMO Services Product Offered
11.5.3 Fareva Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Fareva Main Business Overview
11.5.5 Fareva Latest Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Information
11.6.2 WuXi AppTech Pharmaceutical CDMO Services Product Offered
11.6.3 WuXi AppTech Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 WuXi AppTech Main Business Overview
11.6.5 WuXi AppTech Latest Developments
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Information
11.7.2 WuXi Biologics Pharmaceutical CDMO Services Product Offered
11.7.3 WuXi Biologics Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 WuXi Biologics Main Business Overview
11.7.5 WuXi Biologics Latest Developments
11.8 Siegfried
11.8.1 Siegfried Company Information
11.8.2 Siegfried Pharmaceutical CDMO Services Product Offered
11.8.3 Siegfried Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Siegfried Main Business Overview
11.8.5 Siegfried Latest Developments
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Information
11.9.2 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Services Product Offered
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 FUJIFILM Diosynth Biotechnologies Main Business Overview
11.9.5 FUJIFILM Diosynth Biotechnologies Latest Developments
11.10 Asymchem
11.10.1 Asymchem Company Information
11.10.2 Asymchem Pharmaceutical CDMO Services Product Offered
11.10.3 Asymchem Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Asymchem Main Business Overview
11.10.5 Asymchem Latest Developments
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Information
11.11.2 Pfizer CentreOne Pharmaceutical CDMO Services Product Offered
11.11.3 Pfizer CentreOne Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Pfizer CentreOne Main Business Overview
11.11.5 Pfizer CentreOne Latest Developments
11.12 Delpharm
11.12.1 Delpharm Company Information
11.12.2 Delpharm Pharmaceutical CDMO Services Product Offered
11.12.3 Delpharm Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Delpharm Main Business Overview
11.12.5 Delpharm Latest Developments
11.13 Recipharm
11.13.1 Recipharm Company Information
11.13.2 Recipharm Pharmaceutical CDMO Services Product Offered
11.13.3 Recipharm Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Recipharm Main Business Overview
11.13.5 Recipharm Latest Developments
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Information
11.14.2 AGC Pharma Chemicals Pharmaceutical CDMO Services Product Offered
11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 AGC Pharma Chemicals Main Business Overview
11.14.5 AGC Pharma Chemicals Latest Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Information
11.15.2 Boehringer Ingelheim Pharmaceutical CDMO Services Product Offered
11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Boehringer Ingelheim Main Business Overview
11.15.5 Boehringer Ingelheim Latest Developments
11.16 Vetter
11.16.1 Vetter Company Information
11.16.2 Vetter Pharmaceutical CDMO Services Product Offered
11.16.3 Vetter Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Vetter Main Business Overview
11.16.5 Vetter Latest Developments
11.17 Curia
11.17.1 Curia Company Information
11.17.2 Curia Pharmaceutical CDMO Services Product Offered
11.17.3 Curia Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Curia Main Business Overview
11.17.5 Curia Latest Developments
11.18 Aenova
11.18.1 Aenova Company Information
11.18.2 Aenova Pharmaceutical CDMO Services Product Offered
11.18.3 Aenova Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Aenova Main Business Overview
11.18.5 Aenova Latest Developments
11.19 Porton
11.19.1 Porton Company Information
11.19.2 Porton Pharmaceutical CDMO Services Product Offered
11.19.3 Porton Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Porton Main Business Overview
11.19.5 Porton Latest Developments
11.20 Piramal
11.20.1 Piramal Company Information
11.20.2 Piramal Pharmaceutical CDMO Services Product Offered
11.20.3 Piramal Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Piramal Main Business Overview
11.20.5 Piramal Latest Developments
11.21 Strides Pharma
11.21.1 Strides Pharma Company Information
11.21.2 Strides Pharma Pharmaceutical CDMO Services Product Offered
11.21.3 Strides Pharma Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Strides Pharma Main Business Overview
11.21.5 Strides Pharma Latest Developments
11.22 NextPharma
11.22.1 NextPharma Company Information
11.22.2 NextPharma Pharmaceutical CDMO Services Product Offered
11.22.3 NextPharma Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 NextPharma Main Business Overview
11.22.5 NextPharma Latest Developments
11.23 Famar
11.23.1 Famar Company Information
11.23.2 Famar Pharmaceutical CDMO Services Product Offered
11.23.3 Famar Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Famar Main Business Overview
11.23.5 Famar Latest Developments
11.24 Jubilant
11.24.1 Jubilant Company Information
11.24.2 Jubilant Pharmaceutical CDMO Services Product Offered
11.24.3 Jubilant Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Jubilant Main Business Overview
11.24.5 Jubilant Latest Developments
11.25 Alcami
11.25.1 Alcami Company Information
11.25.2 Alcami Pharmaceutical CDMO Services Product Offered
11.25.3 Alcami Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Alcami Main Business Overview
11.25.5 Alcami Latest Developments
11.26 Euroapi
11.26.1 Euroapi Company Information
11.26.2 Euroapi Pharmaceutical CDMO Services Product Offered
11.26.3 Euroapi Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.26.4 Euroapi Main Business Overview
11.26.5 Euroapi Latest Developments
11.27 Eurofins
11.27.1 Eurofins Company Information
11.27.2 Eurofins Pharmaceutical CDMO Services Product Offered
11.27.3 Eurofins Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.27.4 Eurofins Main Business Overview
11.27.5 Eurofins Latest Developments
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Information
11.28.2 Avid Bioservices Pharmaceutical CDMO Services Product Offered
11.28.3 Avid Bioservices Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.28.4 Avid Bioservices Main Business Overview
11.28.5 Avid Bioservices Latest Developments
11.29 BioVectra
11.29.1 BioVectra Company Information
11.29.2 BioVectra Pharmaceutical CDMO Services Product Offered
11.29.3 BioVectra Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.29.4 BioVectra Main Business Overview
11.29.5 BioVectra Latest Developments
11.30 CPL
11.30.1 CPL Company Information
11.30.2 CPL Pharmaceutical CDMO Services Product Offered
11.30.3 CPL Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.30.4 CPL Main Business Overview
11.30.5 CPL Latest Developments
11.31 Societal CDMO
11.31.1 Societal CDMO Company Information
11.31.2 Societal CDMO Pharmaceutical CDMO Services Product Offered
11.31.3 Societal CDMO Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.31.4 Societal CDMO Main Business Overview
11.31.5 Societal CDMO Latest Developments
11.32 Fermion
11.32.1 Fermion Company Information
11.32.2 Fermion Pharmaceutical CDMO Services Product Offered
11.32.3 Fermion Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.32.4 Fermion Main Business Overview
11.32.5 Fermion Latest Developments
11.33 Ascendia Pharmaceuticals
11.33.1 Ascendia Pharmaceuticals Company Information
11.33.2 Ascendia Pharmaceuticals Pharmaceutical CDMO Services Product Offered
11.33.3 Ascendia Pharmaceuticals Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.33.4 Ascendia Pharmaceuticals Main Business Overview
11.33.5 Ascendia Pharmaceuticals Latest Developments
11.34 Ardena
11.34.1 Ardena Company Information
11.34.2 Ardena Pharmaceutical CDMO Services Product Offered
11.34.3 Ardena Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.34.4 Ardena Main Business Overview
11.34.5 Ardena Latest Developments
11.35 UPM Pharmaceuticals
11.35.1 UPM Pharmaceuticals Company Information
11.35.2 UPM Pharmaceuticals Pharmaceutical CDMO Services Product Offered
11.35.3 UPM Pharmaceuticals Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.35.4 UPM Pharmaceuticals Main Business Overview
11.35.5 UPM Pharmaceuticals Latest Developments
11.36 Groupe Parima
11.36.1 Groupe Parima Company Information
11.36.2 Groupe Parima Pharmaceutical CDMO Services Product Offered
11.36.3 Groupe Parima Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.36.4 Groupe Parima Main Business Overview
11.36.5 Groupe Parima Latest Developments
11.37 TBD Pharmatech
11.37.1 TBD Pharmatech Company Information
11.37.2 TBD Pharmatech Pharmaceutical CDMO Services Product Offered
11.37.3 TBD Pharmatech Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.37.4 TBD Pharmatech Main Business Overview
11.37.5 TBD Pharmatech Latest Developments
11.38 MedPharm
11.38.1 MedPharm Company Information
11.38.2 MedPharm Pharmaceutical CDMO Services Product Offered
11.38.3 MedPharm Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.38.4 MedPharm Main Business Overview
11.38.5 MedPharm Latest Developments
11.39 Lundbeck
11.39.1 Lundbeck Company Information
11.39.2 Lundbeck Pharmaceutical CDMO Services Product Offered
11.39.3 Lundbeck Pharmaceutical CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
11.39.4 Lundbeck Main Business Overview
11.39.5 Lundbeck Latest Developments

12 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Pharmaceutical CDMO Services Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Pharmaceutical CDMO Services Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of API CDMO
Table 4. Major Players of FDF CDMO
Table 5. Major Players of Packaging CDMO
Table 6. Major Players of Clinical CDMO
Table 7. Pharmaceutical CDMO Services Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Pharmaceutical CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Pharmaceutical CDMO Services Market Size Market Share by Type (2021-2026)
Table 10. Major Players of Clinical Stage
Table 11. Major Players of Commercial Stage
Table 12. Major Players of Other
Table 13. Pharmaceutical CDMO Services Market Size CAGR by Development Stage (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global Pharmaceutical CDMO Services Market Size by Development Stage (2021-2026) & ($ millions)
Table 15. Global Pharmaceutical CDMO Services Market Size Market Share by Development Stage (2021-2026)
Table 16. Major Players of Small Molecule CDMO
Table 17. Major Players of Biologics CDMO
Table 18. Major Players of Cell and Gene Therapy CDMO
Table 19. Major Players of Peptide and Oligonucleotide CDMO
Table 20. Pharmaceutical CDMO Services Market Size CAGR by Product Form (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Pharmaceutical CDMO Services Market Size by Product Form (2021-2026) & ($ millions)
Table 22. Global Pharmaceutical CDMO Services Market Size Market Share by Product Form (2021-2026)
Table 23. Pharmaceutical CDMO Services Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Pharmaceutical CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Pharmaceutical CDMO Services Market Size Market Share by Application (2021-2026)
Table 26. Global Pharmaceutical CDMO Services Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Pharmaceutical CDMO Services Revenue Market Share by Player (2021-2026)
Table 28. Pharmaceutical CDMO Services Key Players Head office and Products Offered
Table 29. Pharmaceutical CDMO Services Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Pharmaceutical CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Pharmaceutical CDMO Services Market Size Market Share by Region (2021-2026)
Table 34. Global Pharmaceutical CDMO Services Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Pharmaceutical CDMO Services Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Pharmaceutical CDMO Services Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Pharmaceutical CDMO Services Market Size Market Share by Country (2021-2026)
Table 38. Americas Pharmaceutical CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Pharmaceutical CDMO Services Market Size Market Share by Type (2021-2026)
Table 40. Americas Pharmaceutical CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Pharmaceutical CDMO Services Market Size Market Share by Application (2021-2026)
Table 42. APAC Pharmaceutical CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Pharmaceutical CDMO Services Market Size Market Share by Region (2021-2026)
Table 44. APAC Pharmaceutical CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Pharmaceutical CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Pharmaceutical CDMO Services Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Pharmaceutical CDMO Services Market Size Market Share by Country (2021-2026)
Table 48. Europe Pharmaceutical CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Pharmaceutical CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Pharmaceutical CDMO Services Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Pharmaceutical CDMO Services Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Pharmaceutical CDMO Services Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Pharmaceutical CDMO Services
Table 54. Key Market Challenges & Risks of Pharmaceutical CDMO Services
Table 55. Key Industry Trends of Pharmaceutical CDMO Services
Table 56. Global Pharmaceutical CDMO Services Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Pharmaceutical CDMO Services Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Pharmaceutical CDMO Services Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Pharmaceutical CDMO Services Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Lonza Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 61. Lonza Pharmaceutical CDMO Services Product Offered
Table 62. Lonza Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Lonza Main Business
Table 64. Lonza Latest Developments
Table 65. Catalent Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 66. Catalent Pharmaceutical CDMO Services Product Offered
Table 67. Catalent Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Catalent Main Business
Table 69. Catalent Latest Developments
Table 70. Thermo Fisher Scientific Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 71. Thermo Fisher Scientific Pharmaceutical CDMO Services Product Offered
Table 72. Thermo Fisher Scientific Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Thermo Fisher Scientific Main Business
Table 74. Thermo Fisher Scientific Latest Developments
Table 75. Samsung Biologics Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 76. Samsung Biologics Pharmaceutical CDMO Services Product Offered
Table 77. Samsung Biologics Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Samsung Biologics Main Business
Table 79. Samsung Biologics Latest Developments
Table 80. Fareva Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 81. Fareva Pharmaceutical CDMO Services Product Offered
Table 82. Fareva Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Fareva Main Business
Table 84. Fareva Latest Developments
Table 85. WuXi AppTech Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 86. WuXi AppTech Pharmaceutical CDMO Services Product Offered
Table 87. WuXi AppTech Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. WuXi AppTech Main Business
Table 89. WuXi AppTech Latest Developments
Table 90. WuXi Biologics Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 91. WuXi Biologics Pharmaceutical CDMO Services Product Offered
Table 92. WuXi Biologics Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. WuXi Biologics Main Business
Table 94. WuXi Biologics Latest Developments
Table 95. Siegfried Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 96. Siegfried Pharmaceutical CDMO Services Product Offered
Table 97. Siegfried Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Siegfried Main Business
Table 99. Siegfried Latest Developments
Table 100. FUJIFILM Diosynth Biotechnologies Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 101. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Services Product Offered
Table 102. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. FUJIFILM Diosynth Biotechnologies Main Business
Table 104. FUJIFILM Diosynth Biotechnologies Latest Developments
Table 105. Asymchem Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 106. Asymchem Pharmaceutical CDMO Services Product Offered
Table 107. Asymchem Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Asymchem Main Business
Table 109. Asymchem Latest Developments
Table 110. Pfizer CentreOne Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 111. Pfizer CentreOne Pharmaceutical CDMO Services Product Offered
Table 112. Pfizer CentreOne Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Pfizer CentreOne Main Business
Table 114. Pfizer CentreOne Latest Developments
Table 115. Delpharm Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 116. Delpharm Pharmaceutical CDMO Services Product Offered
Table 117. Delpharm Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Delpharm Main Business
Table 119. Delpharm Latest Developments
Table 120. Recipharm Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 121. Recipharm Pharmaceutical CDMO Services Product Offered
Table 122. Recipharm Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Recipharm Main Business
Table 124. Recipharm Latest Developments
Table 125. AGC Pharma Chemicals Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 126. AGC Pharma Chemicals Pharmaceutical CDMO Services Product Offered
Table 127. AGC Pharma Chemicals Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. AGC Pharma Chemicals Main Business
Table 129. AGC Pharma Chemicals Latest Developments
Table 130. Boehringer Ingelheim Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 131. Boehringer Ingelheim Pharmaceutical CDMO Services Product Offered
Table 132. Boehringer Ingelheim Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Boehringer Ingelheim Main Business
Table 134. Boehringer Ingelheim Latest Developments
Table 135. Vetter Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 136. Vetter Pharmaceutical CDMO Services Product Offered
Table 137. Vetter Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Vetter Main Business
Table 139. Vetter Latest Developments
Table 140. Curia Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 141. Curia Pharmaceutical CDMO Services Product Offered
Table 142. Curia Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Curia Main Business
Table 144. Curia Latest Developments
Table 145. Aenova Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 146. Aenova Pharmaceutical CDMO Services Product Offered
Table 147. Aenova Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. Aenova Main Business
Table 149. Aenova Latest Developments
Table 150. Porton Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 151. Porton Pharmaceutical CDMO Services Product Offered
Table 152. Porton Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 153. Porton Main Business
Table 154. Porton Latest Developments
Table 155. Piramal Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 156. Piramal Pharmaceutical CDMO Services Product Offered
Table 157. Piramal Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 158. Piramal Main Business
Table 159. Piramal Latest Developments
Table 160. Strides Pharma Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 161. Strides Pharma Pharmaceutical CDMO Services Product Offered
Table 162. Strides Pharma Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 163. Strides Pharma Main Business
Table 164. Strides Pharma Latest Developments
Table 165. NextPharma Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 166. NextPharma Pharmaceutical CDMO Services Product Offered
Table 167. NextPharma Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 168. NextPharma Main Business
Table 169. NextPharma Latest Developments
Table 170. Famar Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 171. Famar Pharmaceutical CDMO Services Product Offered
Table 172. Famar Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 173. Famar Main Business
Table 174. Famar Latest Developments
Table 175. Jubilant Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 176. Jubilant Pharmaceutical CDMO Services Product Offered
Table 177. Jubilant Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 178. Jubilant Main Business
Table 179. Jubilant Latest Developments
Table 180. Alcami Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 181. Alcami Pharmaceutical CDMO Services Product Offered
Table 182. Alcami Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 183. Alcami Main Business
Table 184. Alcami Latest Developments
Table 185. Euroapi Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 186. Euroapi Pharmaceutical CDMO Services Product Offered
Table 187. Euroapi Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 188. Euroapi Main Business
Table 189. Euroapi Latest Developments
Table 190. Eurofins Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 191. Eurofins Pharmaceutical CDMO Services Product Offered
Table 192. Eurofins Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 193. Eurofins Main Business
Table 194. Eurofins Latest Developments
Table 195. Avid Bioservices Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 196. Avid Bioservices Pharmaceutical CDMO Services Product Offered
Table 197. Avid Bioservices Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 198. Avid Bioservices Main Business
Table 199. Avid Bioservices Latest Developments
Table 200. BioVectra Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 201. BioVectra Pharmaceutical CDMO Services Product Offered
Table 202. BioVectra Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 203. BioVectra Main Business
Table 204. BioVectra Latest Developments
Table 205. CPL Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 206. CPL Pharmaceutical CDMO Services Product Offered
Table 207. CPL Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 208. CPL Main Business
Table 209. CPL Latest Developments
Table 210. Societal CDMO Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 211. Societal CDMO Pharmaceutical CDMO Services Product Offered
Table 212. Societal CDMO Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 213. Societal CDMO Main Business
Table 214. Societal CDMO Latest Developments
Table 215. Fermion Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 216. Fermion Pharmaceutical CDMO Services Product Offered
Table 217. Fermion Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 218. Fermion Main Business
Table 219. Fermion Latest Developments
Table 220. Ascendia Pharmaceuticals Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 221. Ascendia Pharmaceuticals Pharmaceutical CDMO Services Product Offered
Table 222. Ascendia Pharmaceuticals Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 223. Ascendia Pharmaceuticals Main Business
Table 224. Ascendia Pharmaceuticals Latest Developments
Table 225. Ardena Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 226. Ardena Pharmaceutical CDMO Services Product Offered
Table 227. Ardena Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 228. Ardena Main Business
Table 229. Ardena Latest Developments
Table 230. UPM Pharmaceuticals Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 231. UPM Pharmaceuticals Pharmaceutical CDMO Services Product Offered
Table 232. UPM Pharmaceuticals Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 233. UPM Pharmaceuticals Main Business
Table 234. UPM Pharmaceuticals Latest Developments
Table 235. Groupe Parima Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 236. Groupe Parima Pharmaceutical CDMO Services Product Offered
Table 237. Groupe Parima Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 238. Groupe Parima Main Business
Table 239. Groupe Parima Latest Developments
Table 240. TBD Pharmatech Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 241. TBD Pharmatech Pharmaceutical CDMO Services Product Offered
Table 242. TBD Pharmatech Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 243. TBD Pharmatech Main Business
Table 244. TBD Pharmatech Latest Developments
Table 245. MedPharm Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 246. MedPharm Pharmaceutical CDMO Services Product Offered
Table 247. MedPharm Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 248. MedPharm Main Business
Table 249. MedPharm Latest Developments
Table 250. Lundbeck Details, Company Type, Pharmaceutical CDMO Services Area Served and Its Competitors
Table 251. Lundbeck Pharmaceutical CDMO Services Product Offered
Table 252. Lundbeck Pharmaceutical CDMO Services Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 253. Lundbeck Main Business
Table 254. Lundbeck Latest Developments

List of Figures
Figure 1. Pharmaceutical CDMO Services Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Pharmaceutical CDMO Services Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Pharmaceutical CDMO Services Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Pharmaceutical CDMO Services Sales Market Share by Country/Region (2025)
Figure 8. Pharmaceutical CDMO Services Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Pharmaceutical CDMO Services Market Size Market Share by Type in 2025
Figure 10. Global Pharmaceutical CDMO Services Market Size Market Share by Development Stage in 2025
Figure 11. Global Pharmaceutical CDMO Services Market Size Market Share by Product Form in 2025
Figure 12. Pharmaceutical CDMO Services in Pharmaceutical Company
Figure 13. Global Pharmaceutical CDMO Services Market: Pharmaceutical Company (2021-2026) & ($ millions)
Figure 14. Pharmaceutical CDMO Services in Biotechnology Company
Figure 15. Global Pharmaceutical CDMO Services Market: Biotechnology Company (2021-2026) & ($ millions)
Figure 16. Pharmaceutical CDMO Services in Other
Figure 17. Global Pharmaceutical CDMO Services Market: Other (2021-2026) & ($ millions)
Figure 18. Global Pharmaceutical CDMO Services Market Size Market Share by Application in 2025
Figure 19. Global Pharmaceutical CDMO Services Revenue Market Share by Player in 2025
Figure 20. Global Pharmaceutical CDMO Services Market Size Market Share by Region (2021-2026)
Figure 21. Americas Pharmaceutical CDMO Services Market Size 2021-2026 ($ millions)
Figure 22. APAC Pharmaceutical CDMO Services Market Size 2021-2026 ($ millions)
Figure 23. Europe Pharmaceutical CDMO Services Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Pharmaceutical CDMO Services Market Size 2021-2026 ($ millions)
Figure 25. Americas Pharmaceutical CDMO Services Value Market Share by Country in 2025
Figure 26. United States Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Pharmaceutical CDMO Services Market Size Market Share by Region in 2025
Figure 31. APAC Pharmaceutical CDMO Services Market Size Market Share by Type (2021-2026)
Figure 32. APAC Pharmaceutical CDMO Services Market Size Market Share by Application (2021-2026)
Figure 33. China Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 37. India Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Pharmaceutical CDMO Services Market Size Market Share by Country in 2025
Figure 40. Europe Pharmaceutical CDMO Services Market Size Market Share by Type (2021-2026)
Figure 41. Europe Pharmaceutical CDMO Services Market Size Market Share by Application (2021-2026)
Figure 42. Germany Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 43. France Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Pharmaceutical CDMO Services Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Pharmaceutical CDMO Services Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Pharmaceutical CDMO Services Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Pharmaceutical CDMO Services Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 56. APAC Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 57. Europe Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 59. United States Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 60. Canada Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 61. Mexico Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 62. Brazil Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 63. China Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 64. Japan Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 65. Korea Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 67. India Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 68. Australia Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 69. Germany Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 70. France Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 71. UK Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 72. Italy Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 73. Russia Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 74. Egypt Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 75. South Africa Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 76. Israel Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 77. Turkey Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)
Figure 78. Global Pharmaceutical CDMO Services Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Pharmaceutical CDMO Services Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Pharmaceutical CDMO Services Market Size 2027-2032 ($ millions)